Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The stage is set for revolutionary advances in medicine and biotechnology it is claimed, following substantial investment in cryo-electron microscopy in Oxford awarded by the Wellcome Trust in its April 2016 funding round.

The Collaborative Award in Science, headed by the Dunn School's Susan Lea, has been made to a cross - departmental team. 

Professor Lea said:  “The cell is the fundamental unit of all life and there is an impending transformation in our understanding of how it functions. This will set the stage for a step-change in medicine and biotechnology, as well as being likely to found whole new industries – by analogy to the molecular biology revolution of the 20th century. These exciting changes are being catalysed by many advances, but the most direct technological revolution has been in cryo-electron microscopy.”

Read more (Sir William Dunn School of Pathology website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.